← brief for 2026-08-21 · Slowing decline

Short-Term Peri-Procedural Dapagliflozin for Prevention of Contrast-Induced Acute Kidney Injury in Diabetic Patients Undergoing Coronary Computed Tomographic Angiography: A Prospective Randomized Double-Blind Placebo-Controlled Study.

Article B Peer reviewed Small trial

Key takeaways

Doctors tested whether the diabetes drug dapagliflozin can protect the kidneys from the dye used in heart scans. That dye can sometimes injure the kidneys. This was a randomized, double-blind trial with a dummy pill for comparison, so neither patients nor doctors knew who got the real drug. It screened 352 diabetic patients getting a heart CT scan, and it looked only at short-term effects around the scan.

Who did this work

Zheng T · Zhang L · Hu J · Cheng X · Zhong Y · Huang X · Gong L · Zhan B

Source

Article · PubMed, the drug frontier · 2026 Aug 20
https://pubmed.ncbi.nlm.nih.gov/42623314/